{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:13:22Z","timestamp":1787004802107,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1053\/j.gastro.2014.08.044","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T00:50:58Z","timestamp":1410828658000},"page":"981-989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Development of Drugs to Target Interactions Between Leukocytes and Endothelial Cells and Treatment Algorithms for Inflammatory Bowel Diseases"],"prefix":"10.1053","volume":"147","author":[{"given":"Silvio","family":"Danese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"Pan\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2014.08.044_bib1","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","article-title":"Inflammatory bowel disease: cause and immunobiology","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2014.08.044_bib2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00535-010-0219-3","article-title":"New pathophysiological insights and modern treatment of IBD","volume":"45","author":"Engel","year":"2010","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1053\/j.gastro.2014.08.044_bib3","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review","volume":"106","author":"Billioud","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2014.08.044_bib4","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2014.08.044_bib5","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1365-2036.2011.04599.x","article-title":"Review article: remission rates achievable by current therapies for inflammatory bowel disease","volume":"33","author":"Peyrin-Biroulet","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2014.08.044_bib6","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.3748\/wjg.v12.i29.4628","article-title":"Novel strategies for the treatment of inflammatory bowel disease: selective inhibition of cytokines and adhesion molecules","volume":"12","author":"Nakamura","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2014.08.044_bib7","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/gutjnl-2011-300904","article-title":"New therapies for inflammatory bowel disease: from the bench to the bedside","volume":"61","author":"Danese","year":"2012","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2014.08.044_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(08)60995-2","article-title":"Crohn's disease: beyond antagonists of tumour necrosis factor","volume":"372","author":"Peyrin-Biroulet","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2014.08.044_bib9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.dld.2005.03.013","article-title":"Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation","volume":"37","author":"Danese","year":"2005","journal-title":"Dig Liver Dis"},{"key":"10.1053\/j.gastro.2014.08.044_bib10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/sj.bjp.0702328","article-title":"Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention","volume":"126","author":"Panes","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1053\/j.gastro.2014.08.044_bib11","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0016-5085(99)70070-3","article-title":"VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis","volume":"116","author":"Sans","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2014.08.044_bib12","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/0016-5085(95)90138-8","article-title":"Role of leukocyte-endothelial cell adhesion in radiation-induced microvascular dysfunction in rats","volume":"108","author":"Panes","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2014.08.044_bib13","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1053\/gast.1997.v112.pm9178682","article-title":"Enhanced leukocyte binding by intestinal microvascular endothelial cells in\u00a0inflammatory bowel disease","volume":"112","author":"Binion","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2014.08.044_bib14","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A\u00a0randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2014.08.044_bib15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2014.08.044_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2014.08.044_bib17","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2014.08.044_bib18","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2014.08.044_bib19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/apt.12639","article-title":"Review article: anti-adhesion therapies for inflammatory bowel disease","volume":"39","author":"Lobaton","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2014.08.044_bib20","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2014.08.044_bib21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy","volume":"354","author":"Yousry","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2014.08.044_bib22","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2174\/13894501113146660206","article-title":"Vedolizumab for the treatment of\u00a0IBD: a selective therapeutic approach targeting pathogenic a4b7 cells","volume":"14","author":"Jovani","year":"2013","journal-title":"Curr Drug Targets"},{"key":"10.1053\/j.gastro.2014.08.044_bib23","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/ibd\/17.supplement1.S4b","article-title":"The gastrointestinal-selective biologic vedolizumab does not impair immune surveillance of the central nervous system in non-human primates","volume":"17","author":"Fedyk","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2014.08.044_bib24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2014.08.044_bib25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2014.08.044_bib26","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2014.08.044_bib27","doi-asserted-by":"crossref","unstructured":"Sands B, Hanauer S, Danese S, et\u00a0al. Reductions in corticosteroid use in patients with ulcerative colitis or Crohn's disease treated with vedolizumab. Presented at: 21st United European Gastroenterology Week; October 12\u201316, 2013; Berlin, Germany.","DOI":"10.14309\/00000434-201310001-01676"},{"key":"10.1053\/j.gastro.2014.08.044_bib28","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa042982","article-title":"Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin","volume":"352","author":"Feagan","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2014.08.044_bib29","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.cgh.2008.06.007","article-title":"Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin","volume":"6","author":"Feagan","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2014.08.044_bib30","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1136\/gutjnl-2011-301769","article-title":"A\u00a0randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis","volume":"62","author":"Rutgeerts","year":"2013","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2014.08.044_bib31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial","volume":"26","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2014.08.044_bib32","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/gut.2010.226548","article-title":"The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study","volume":"60","author":"Vermeire","year":"2011","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2014.08.044_bib33","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1053\/gast.2001.27154","article-title":"CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease","volume":"121","author":"Papadakis","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2014.08.044_bib34","doi-asserted-by":"crossref","first-page":"e60094","DOI":"10.1371\/journal.pone.0060094","article-title":"A\u00a0randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease","volume":"8","author":"Keshav","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2014.08.044_bib35","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/gutjnl-2012-303424","article-title":"Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study","volume":"63","author":"Mayer","year":"2014","journal-title":"Gut"},{"issue":"suppl","key":"10.1053\/j.gastro.2014.08.044_bib36","article-title":"Phase IIB, randomized, placebo-controlled evaluation of the efficacy and safety of induction therapy with eldelumab (anti-IP-10 antibody; BMS-936557) in patients with active\u00a0ulcerative colitis (abstr)","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2014.08.044_bib37","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/WCO.0b013e328360279f","article-title":"Progressive multifocal leukoencephalopathy in patients with multiple sclerosis","volume":"26","author":"Baldwin","year":"2013","journal-title":"Curr Opin Neurol"},{"key":"10.1053\/j.gastro.2014.08.044_bib38","unstructured":"Biogen Idec Inc. Highlights of prescribing information: Tysabri 2013. http:\/\/www.tysabri.com\/pdfs\/I61061-13_PI.pdf."},{"key":"10.1053\/j.gastro.2014.08.044_bib39","unstructured":"Biogen Idec Inc. TYSABRI: Highlights of prescribing information 2013 [updated December 2013]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125104s840s847s889lbl.pdf."},{"key":"10.1053\/j.gastro.2014.08.044_bib40","doi-asserted-by":"crossref","unstructured":"D'Haens G, Vermeire S, Cataldi F, et\u00a0al, eds. Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn's disease patients who are anti-TNF inadequate responders: results from the TOSCA study. Presented at: 9th Congress of the European Crohn\u2019s and Colitis Organisation; February 20\u201322, 2014; Copenhagen, Denmark.","DOI":"10.1016\/S1873-9946(14)60008-8"},{"key":"10.1053\/j.gastro.2014.08.044_bib41","doi-asserted-by":"crossref","unstructured":"Clifford DB, McAuliffe M, Stephens K, et\u00a0al. Risk Assessment and minimization for progressive multifocal leukoencephalopathy (PML RAMP): a program to assess for potential early signs and symptoms of PML during clinical development of vedolizumab. Presented at: 78th Annual Scientific Meeting of the American College of Gastroenterology; October 11\u201316, 2013; San Diego, CA.","DOI":"10.14309\/00000434-201310001-01673"},{"key":"10.1053\/j.gastro.2014.08.044_bib42","unstructured":"Colombe J-F, Sands B, Hanauer S, et\u00a0al. Long-term safety of vedolizumab for the treatment of ulcerative colitis or Crohn\u2019s disease. Presented at: 78th Annual Scientific Meeting of the American College of Gastroenterology; October 11\u201316, 2013; San Diego, CA."},{"key":"10.1053\/j.gastro.2014.08.044_bib43","doi-asserted-by":"crossref","first-page":"704","DOI":"10.7326\/M13-2403","article-title":"Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis","volume":"160","author":"Danese","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2014.08.044_bib44","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2014.08.044_bib45","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1038\/ajg.2010.345","article-title":"A\u00a0multicenter experience with infliximab for ulcerative colitis: outcomes\u00a0and predictors of response, optimization, colectomy, and hospitalization","volume":"105","author":"Oussalah","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2014.08.044_bib46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2014.08.044_bib47","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2014.08.044_bib48","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2014.08.044_bib49","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2014.08.044_bib50","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2014.08.044_bib51","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2014.08.044_bib52","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/ajg.2010.78","article-title":"Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data","volume":"105","author":"Schreiber","year":"2010","journal-title":"Am J Gastroenterol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508514010877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508514010877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T15:10:10Z","timestamp":1758035410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508514010877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0016508514010877"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2014.08.044","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of Drugs to Target Interactions Between Leukocytes and Endothelial Cells and Treatment Algorithms for Inflammatory Bowel Diseases","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2014.08.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}